查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631257

中低收入國家鴉片類藥物替代療法的全球市場 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2032年)

Low and Middle Income Countries Opioid Substitution Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 200 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

中低收入國家的鴉片類藥物替代療法 (OST) 市場規模預計將從 2025 年的 8.556 億美元增長到 2032 年的 13.91 億美元，複合年增長率為 7.20%。 OST 透過以美沙酮或丁丙諾啡等受醫學監督的替代品取代非法鴉片類藥物來減少危害並幫助個人克服毒癮。 OST 最大限度地降低了過量用藥、血源性疾病傳播和其他併發症的風險，同時促進了患者重新融入社會。

在中低收入國家，OST 對於解決與鴉片類藥物濫用相關的公共衛生課題至關重要。市場成長的動力來自於人們對 OST 有效性的認識不斷提高、國際和政府支持以及服務交付方面的創新。市場進入者的機會包括與醫療保健提供者合作，創建具有文化針對性的 OST 解決方案，並利用遠距醫療擴大服務不足地區的醫療服務。

由於人們越來越認識到阿片類藥物成癮是一個公共衛生問題，中低收入國家的鴉片類藥物替代療法市場持續成長。各國政府和國際組織的支持有助於OST計畫的實施。市場參與者可以透過合作提供可訪問的本地化解決方案並採用技術來改善患者的治療效果，從而抓住機會。

向本報告提供中低收入國家鴉片類藥物替代療法市場相關調查，提供市場概要，以及各類藥物，各適應症，各流通管道，各地區趨勢，及市場參與市場企業的競爭趨勢等資訊。

目錄

第1章 摘要整理

第2章 市場概要

  • 市場定義和市場區隔
  • 市場動態
  • 價值鏈分析
  • 波特的五力分析
  • COVID-19影響分析
  • 經濟概要
  • 大環境分析

第3章 價格分析，2019年～2023年

第4章 中低收入國家鴉片類藥物替代療法市場預測，2019年～2032年

  • 中低收入國家鴉片類藥物替代療法市場預測，各類藥物，規模(100萬美元)，數量(事)，2019年～2032年
  • 中低收入國家鴉片類藥物替代療法市場預測，各適應症，規模(100萬美元)，數量(事)，2019年～2032年
  • 中低收入國家鴉片類藥物替代療法市場預測，各流通管道，規模(100萬美元)，數量(事)，2019年～2032年
  • 中低收入國家鴉片類藥物替代療法市場預測，各地區，規模(100萬美元)，數量(事)，2019年～2032年

第5章 北美的中低收入國家鴉片類藥物替代療法市場預測，2019年～2032年

第6章 歐洲的中低收入國家鴉片類藥物替代療法市場預測，2019年～2032年

第7章 亞太地區的中低收入國家鴉片類藥物替代療法市場預測，2019年～2032年

第8章 南美的中低收入國家鴉片類藥物替代療法市場預測，2019年～2032年

第9章 中東·非洲的中低收入國家鴉片類藥物替代療法市場預測，2019年～2032年

第10章 競爭情形

  • 各解決方案類型和各適應症熱圖
  • 企業市場佔有率分析，2024年
  • 競爭儀表板
  • 企業簡介
    • Indivior Inc.
    • Alkermes, Inc
    • Mundipharma GmbH
    • Viatris Inc
    • Intas Pharmaceuticals
    • Camurus

第11章 附錄

簡介目錄

The global Low and Middle Income Countries Opioid Substitution Therapy (OST) Market is projected to grow at a CAGR of 7.20%, increasing from US$ 855.6 million in 2025 to US$ 1,391 million by 2032. OST involves replacing illicit opioids with medically supervised alternatives like methadone or buprenorphine, reducing harm and supporting individuals in overcoming addiction. OST minimizes risks of overdose, blood-borne disease transmission, and other complications while aiding reintegration into society.

In LMICs, OST is vital for addressing public health challenges linked to opioid misuse. The market's growth is fueled by rising awareness of OST's effectiveness, international and governmental support, and innovations in service delivery. Opportunities for market players include partnerships with healthcare providers to create culturally appropriate OST solutions and leveraging telemedicine to expand access in underserved areas.

The OST market in LMICs continues to grow due to increased recognition of opioid addiction as a public health concern. Government and international organization support has bolstered OST program implementation. Market players can capitalize on opportunities by collaborating to deliver accessible, region-specific solutions and incorporating technology to enhance patient outcomes.

Market Growth Drivers

1.Recognition of Public Health Impact

Governments and international health organizations increasingly recognize the burden of opioid addiction. This has led to proactive strategies, with OST emerging as a key harm reduction tool benefiting individuals and communities.

2.Policy Support and Collaboration

Collaborative efforts between governments, NGOs, and international organizations have promoted OST adoption. Supportive policies and integration into healthcare systems ensure broader program reach and impact.

3.Rising Awareness and Healthcare Investments

Increased awareness about opioid addiction and societal impacts, along with healthcare infrastructure investments, drive market growth. Advocacy campaigns promote harm reduction strategies and OST acceptance.

Market Restraints

1.Regulatory Challenges

Diverse regulatory frameworks across LMICs create significant hurdles. Variations in licensing, medication restrictions, and government support hinder OST adoption. Harmonizing regulations is critical for market growth.

2.Implementation Barriers

Limited healthcare infrastructure and insufficient provider training challenge effective OST deployment. Addressing these barriers requires capacity-building initiatives and strategic collaborations.

Business Opportunities

1.Telemedicine Expansion

Telemedicine can improve OST access in regions with limited healthcare infrastructure. Remote consultations and support services address geographical barriers, ensuring consistent care delivery.

2.Strategic Collaborations

Partnerships with healthcare providers, NGOs, and governments can enhance OST delivery. Collaborative efforts like training programs and awareness campaigns foster sustainable healthcare ecosystems.

3.Technological Innovations

Advanced OST solutions tailored to regional needs, such as digital tools for monitoring adherence, present growth potential. Investing in technology-driven systems can improve outcomes and expand market reach.

Regional Analysis

1.Europe

Europe leads the LMICs OST market with progressive harm reduction strategies and strong healthcare systems. Evidence-based policies and collaborations ensure widespread OST adoption. Europe's focus on personalized care and harm reduction establishes it as a model for managing opioid dependence effectively.

2.South Asia and the Pacific

South Asia and the Pacific is the fastest-growing region, driven by health policies and increasing public awareness. Government initiatives, international collaborations, and recognition of OST benefits position this region for rapid expansion.

3.Latin America, Middle East & Africa

Emerging markets in these regions offer untapped opportunities. Increased government efforts and growing investments in healthcare infrastructure drive OST adoption.

Competitive Analysis

Key players in the OST Market include:

  • Indivior Inc.
  • Alkermes, Inc.
  • Mundipharma GmbH
  • Viatris Inc.
  • Intas Pharmaceuticals
  • Camurus

These companies focus on innovation, collaborations, and targeted regional strategies to strengthen their market positions.

Low and Middle Income Countries Opioid Substitution Therapy Market Segmentation

1.By Drug Class

  • Opioid Antagonists
  • Naloxone
  • Naltrexone
  • Opioid Agonists and Partial Agonists
  • Methadone
  • Buprenorphine

2.By Indication

  • Pain Management
  • Opioid Withdrawal/Opioid Use Disorder (OUD)
  • Alcohol De-addiction
  • Depression

3.By Distribution Channel

  • Government-supported Centers/NGOs/Tenders
  • Institutional Sales
  • Hospitals
  • Psychiatric Clinics
  • Retail Pharmacies
  • Online Sales

4.By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Low and Middle Income Countries Opioid Substitution Therapy Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Economic Overview
    • 2.6.1. World Economic Projections
  • 2.7. PESTLE Analysis

3. Price Analysis, 2019 - 2023

  • 3.1. Global Average Price Analysis by Drug Class, 2019 - 2023
  • 3.2. Prominent Factor Affecting Low and Middle Income Countries Opioid Substitution Therapy Prices
  • 3.3. Global Average Price Analysis by Region

4. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 4.1. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Opioid Antagonists
      • 4.1.1.2. Naloxone
      • 4.1.1.3. Naltrexone
      • 4.1.1.4. Opioid Agonists and Partial Agonists
      • 4.1.1.5. Methadone
      • 4.1.1.6. Buprenorphine
  • 4.2. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Pain Management
      • 4.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 4.2.1.3. Alcohol De-addiction
      • 4.2.1.4. Depression
  • 4.3. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Government-supported Centers/NGO's/Tenders
      • 4.3.1.2. Institutional Sales
      • 4.3.1.3. Hospitals
      • 4.3.1.4. Psychiatric clinics
      • 4.3.1.5. Retail Pharmacies
      • 4.3.1.6. Online Sales
  • 4.4. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Region, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. North America
      • 4.4.1.2. Europe
      • 4.4.1.3. Asia Pacific
      • 4.4.1.4. Latin America
      • 4.4.1.5. Middle East & Africa

5. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 5.1. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Opioid Antagonists
      • 5.1.1.2. Naloxone
      • 5.1.1.3. Naltrexone
      • 5.1.1.4. Opioid Agonists and Partial Agonists
      • 5.1.1.5. Methadone
      • 5.1.1.6. Buprenorphine
  • 5.2. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Pain Management
      • 5.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 5.2.1.3. Alcohol De-addiction
      • 5.2.1.4. Depression
  • 5.3. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Government-supported Centers/NGO's/Tenders
      • 5.3.1.2. Institutional Sales
      • 5.3.1.3. Hospitals
      • 5.3.1.4. Psychiatric clinics
      • 5.3.1.5. Retail Pharmacies
      • 5.3.1.6. Online Sales
    • 5.3.2. Attractiveness Analysis
  • 5.4. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.2. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.3. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.4. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.5. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.6. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

6. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 6.1. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Opioid Antagonists
      • 6.1.1.2. Naloxone
      • 6.1.1.3. Naltrexone
      • 6.1.1.4. Opioid Agonists and Partial Agonists
      • 6.1.1.5. Methadone
      • 6.1.1.6. Buprenorphine
  • 6.2. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Pain Management
      • 6.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 6.2.1.3. Alcohol De-addiction
      • 6.2.1.4. Depression
  • 6.3. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Government-supported Centers/NGO's/Tenders
      • 6.3.1.2. Institutional Sales
      • 6.3.1.3. Hospitals
      • 6.3.1.4. Psychiatric clinics
      • 6.3.1.5. Retail Pharmacies
      • 6.3.1.6. Online Sales
    • 6.3.2. Attractiveness Analysis
  • 6.4. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.2. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.3. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.4. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.5. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.6. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.7. France Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.8. France Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.9. France Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.10. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.11. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.12. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.13. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.14. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.15. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.16. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.17. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.18. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.19. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.20. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.21. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

7. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 7.1. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Opioid Antagonists
      • 7.1.1.2. Naloxone
      • 7.1.1.3. Naltrexone
      • 7.1.1.4. Opioid Agonists and Partial Agonists
      • 7.1.1.5. Methadone
      • 7.1.1.6. Buprenorphine
  • 7.2. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Pain Management
      • 7.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 7.2.1.3. Alcohol De-addiction
      • 7.2.1.4. Depression
  • 7.3. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Government-supported Centers/NGO's/Tenders
      • 7.3.1.2. Institutional Sales
      • 7.3.1.3. Hospitals
      • 7.3.1.4. Psychiatric clinics
      • 7.3.1.5. Retail Pharmacies
      • 7.3.1.6. Online Sales
    • 7.3.2. Attractiveness Analysis
  • 7.4. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. China Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.2. China Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.3. China Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.4. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.5. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.6. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.7. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.8. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.9. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.10. India Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.11. India Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.12. India Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.13. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.14. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.15. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.16. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.17. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.18. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

8. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 8.1. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Opioid Antagonists
      • 8.1.1.2. Naloxone
      • 8.1.1.3. Naltrexone
      • 8.1.1.4. Opioid Agonists and Partial Agonists
      • 8.1.1.5. Methadone
      • 8.1.1.6. Buprenorphine
  • 8.2. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Pain Management
      • 8.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 8.2.1.3. Alcohol De-addiction
      • 8.2.1.4. Depression
  • 8.3. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Government-supported Centers/NGO's/Tenders
      • 8.3.1.2. Institutional Sales
      • 8.3.1.3. Hospitals
      • 8.3.1.4. Psychiatric clinics
      • 8.3.1.5. Retail Pharmacies
      • 8.3.1.6. Online Sales
    • 8.3.2. Attractiveness Analysis
  • 8.4. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.2. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.3. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.4. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.5. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.6. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.7. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.8. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.9. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.10. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.11. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.12. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

9. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 9.1. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Opioid Antagonists
      • 9.1.1.2. Naloxone
      • 9.1.1.3. Naltrexone
      • 9.1.1.4. Opioid Agonists and Partial Agonists
      • 9.1.1.5. Methadone
      • 9.1.1.6. Buprenorphine
  • 9.2. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Pain Management
      • 9.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 9.2.1.3. Alcohol De-addiction
      • 9.2.1.4. Depression
  • 9.3. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Government-supported Centers/NGO's/Tenders
      • 9.3.1.2. Institutional Sales
      • 9.3.1.3. Hospitals
      • 9.3.1.4. Psychiatric clinics
      • 9.3.1.5. Retail Pharmacies
      • 9.3.1.6. Online Sales
    • 9.3.2. Attractiveness Analysis
  • 9.4. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.2. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.3. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.4. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.5. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.6. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.7. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.8. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.9. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.10. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.11. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.12. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.13. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.14. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.15. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

10. Competitive Landscape

  • 10.1. By Solution Type vs by Indication Heatmap
  • 10.2. Company Market Share Analysis, 2024
  • 10.3. Competitive Dashboard
  • 10.4. Company Profiles
    • 10.4.1. Indivior Inc.
      • 10.4.1.1. Company Overview
      • 10.4.1.2. Product Portfolio
      • 10.4.1.3. Financial Overview
      • 10.4.1.4. Business Strategies and Development
    • 10.4.2. Alkermes, Inc
      • 10.4.2.1. Company Overview
      • 10.4.2.2. Product Portfolio
      • 10.4.2.3. Financial Overview
      • 10.4.2.4. Business Strategies and Development
    • 10.4.3. Mundipharma GmbH
      • 10.4.3.1. Company Overview
      • 10.4.3.2. Product Portfolio
      • 10.4.3.3. Financial Overview
      • 10.4.3.4. Business Strategies and Development
    • 10.4.4. Viatris Inc
      • 10.4.4.1. Company Overview
      • 10.4.4.2. Product Portfolio
      • 10.4.4.3. Financial Overview
      • 10.4.4.4. Business Strategies and Development
    • 10.4.5. Intas Pharmaceuticals
      • 10.4.5.1. Company Overview
      • 10.4.5.2. Product Portfolio
      • 10.4.5.3. Financial Overview
      • 10.4.5.4. Business Strategies and Development
    • 10.4.6. Camurus
      • 10.4.6.1. Company Overview
      • 10.4.6.2. Product Portfolio
      • 10.4.6.3. Financial Overview
      • 10.4.6.4. Business Strategies and Development

11. Appendix

  • 11.1. Research Methodology
  • 11.2. Report Assumptions
  • 11.3. Acronyms and Abbreviations